Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-3985

AGS-KRAS-G12D-Y96D-KI Cell Line

Home » AGS-KRAS-G12D-Y96D-KI Cell Line

Background of AGS-KRAS-G12D-Y96D-KI Cell Line

The KRAS gene, encoding the Kirsten rat sarcoma viral oncogene homolog, is a member of the RAS family of small GTPases. KRAS plays a crucial role in transmitting signals from cell surface receptors to downstream effectors, primarily through the MAPK/ERK and PI3K/AKT signaling pathways. These pathways regulate various cellular processes, including proliferation, differentiation, survival, and apoptosis.Recent advances in understanding the molecular mechanisms of KRAS signaling and the development of targeted therapies have opened new avenues for treating KRAS-driven cancers. Small molecule inhibitors that directly target mutant KRAS proteins, such as AMG 510 and MRTX849, have shown promising results in clinical trials, offering hope for patients with previously untreatable cancers.

Specifications

Catalog Number:
KC-3985
Cell Line Name:
AGS-KRAS-G12D-Y96D-KI Cell Line
Clone Number
2A6
Host Cell Line:
AGS
Description:
Stable AGS clone expressing endogenous KRAS gene bearing Y96D mutations, No.2A6
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% DMEM+20% FBS+10% DMSO
Propagation Medium:
DMEM+10% FBS
Selection Marker:
NA
Morphology:
Epithelial
Subculture:
Split saturated culture 1:3-1:6 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 30 hours
Mycoplasma Status:
Negative
In Vivo Validation:
Yes

Cell Line Generation

AGS-KRAS-G12D-Y96D-KI cell line was generated using the CRISPR method.

Characterization

Figure 1: Characterization of AGS-KRAS-G12D-Y96D-KI cell line stable clone using PCR sequencing.

Figure 2: Characterization of AGS-KRAS-G12D-Y96D-KI cell line stable clone using RT-PCR sequencing.

Figure 3. Characterization of dose-response curves for KRAS inhibitors on AGS and AGS-KRAS-G12D-Y96D-KI cells.

Cell Resuscitation

  1. Prewarm culture medium (DMEM + 10% FBS)in a 37°C water bath.
  2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
  3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
  4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
  5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
  6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
  7. Incubate the flask at 37°C, 5% CO2 incubator.
  8. Split saturated culture 1:3-1:6 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

  1. Prepare the freezing medium (70% DMEM + 20% FBS + 10% DMSO) fresh immediately before use.
  2. Keep the freezing medium on ice and label cryovials.
  3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
  5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
  6. Aliquot 1 mL of the cell suspension into each cryovial.
  7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
  8. Transfer vials to liquid nitrogen for long-term storage

References

  1. Prior, I. A., Lewis, P. D., & Mattos, C. (2012). A comprehensive survey of ras mutations in cancer.Cancer Research, 72(10), 2457-2467. https://doi.org/10.1158/0008-5472.CAN-11-2612
  2. Jänne, P. A., & Shaw, A. T. (2019). Targeting KRAS-mutant cancers with KRAS(G12C) inhibitors.New England Journal of Medicine, 381(14), 1301-1303. https://doi.org/10.1056/NEJMp1909644